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ABSTRACT
ObjectivesTosystematicallyassessthetypeofoutcomes
selectedandtheprevalenceofpatientreportedoutcomes
in contemporary cardiovascular trials and to quantify any
misuse or underuseof patient reportedoutcomes using a
specially developed tool that would allow estimation of
the relevance of such outcomes to clinical decision
making.
Design Systematic review.
Data sources Medline and Embase.
Study selection Randomised controlled trials of the
treatment for or prevention of cardiovascular disease
published in 10 leading general medical and cardiology
journals from January 2005 to December 2008.
Results Primary outcomes were patient important (death,
morbidity,orpatientreportedoutcomes)inonly93of413
trials (23%, SE 2%), whereas another 92 (22%, SE 2%)
combinedtheseoutcomeswithotherlessimportantones
into a composite. Sixty five trials (16%; SE 2%) used at
least one instrument to measure patient reported
outcomes, mostly in trials where such information would
have been important or crucial for clinical decision
making (52 trials). Patient reported outcomes were
judged to be of little incremental value to a large number
of, mostly explanatory, cardiovascular trials (152 trials).
However, many trials in which patient reported outcomes
would have been important or crucial for clinical decision
making did not report such outcomes (122 of 174 trials,
70%). These included several trials that primarily aimed
to improve symptoms or functional status, trials that
tested interventions with a considerable potential for
causing harm (mainly bleeding) that were not
meaningfully measured, and trials with composite
outcomes that were dominated by outcomes of
questionable importance to patients.
Conclusions Despite a continued rise in the reporting of
patient reported outcomes with no evidence for their
misuse in more recent cardiovascular trials, they seem to
bestillunderusedoncetheirrelevancetoclinicaldecision
making has been taken into account. This was largely
explained by inappropriate use of composite outcomes
and inadequate measurement of harms.
INTRODUCTION
The ultimate goal of clinical trials is to identify inter-
ventionstobenefitfuturepatients.Theselectionofbest
variables for measuring such benefits or harms is com-
plex, however, and has been open to debate.
12 Per-
ceived from the patients’ perspective, medical
interventions should either prevent premature death
or improve health related quality of life. Instruments
for patient reported outcomes allow measurement of
the effect of interventions from the patients’
perspective.
3Suchinstrumentscanbeparticularlyuse-
ful when interventions aim to improve symptoms and
functionalstatus(forexample,thewalkingimpairment
questionnaire
4) or health related quality of life in a
wider sense (for example the chronic heart failure
questionnaire
5).
Earlier studies have suggested that patient reported
outcomes might have been underused in randomised
trials in general
67and more so in cardiovascular trials.
6
These studies were, however, published several years
ago when suitable instruments for measuring patient
reported outcomes were limited and only a few
researchers had the necessary expertise for using
them. More importantly, no information is available
on the relevance of the use of patient reported out-
comes to contemporary cardiovascular trials. It may
be that such instruments are less relevant to many
cardiovascular trials, where traditionally the focus has
been on major clinical outcomes such as myocardial
infarction and stroke rather than the relief of symp-
toms. Furthermore, many cardiovascular trials are
concerned with biological effects of interventions,
without any intentions on changing clinical practice.
For example, when investigators seek to understand
the effect of high dose folic acid on coronary
vasodilation
8 or to explore the pharmacodynamics
and pharmacokinetics of different dosages of an anti-
platelet agent,
9 the measurement of patient reported
outcomes is expectedlyof little value. Therefore, with-
outassessmentoftherelevanceofpatientreportedout-
comes to individual trials and their impact on clinical
decision making, no reliable conclusions can be made
about their misuse or underuse.
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prevalence of patient reported outcomes in recent
cardiovascular trials. To quantify any current misuse
or underuse of patient reported outcomes we further
sought to develop a tool that would allow estimation
of the relevance of such outcomes to clinical decision
making and applied it to a set of cardiovascular trials.
METHODS
WesearchedMedlineandEmbaseforarticleswithany
of the subject terms “cardiovascular diseases” or
“cardiovascular agents” published between January
2005 and December 2008 in any of the followinglead-
ing general medical or cardiology journals: New Eng-
land Journal of Medicine, Lancet, JAMA, Annals of Internal
Medicine, PLoS Medicine, BMJ, Circulation, Journal of the
American College of Cardiology, Circulation Research, and
European Heart Journal (see web extra appendix 1 for
the detailed search strategy).
Review methods and data extraction
Figure1summarisestheretrievalandselectionprocess
for studies. The combined searches yielded 2374
reports, of which 1376 were excluded on the basis of
titles and abstracts. The remaining 998 reports were
allocated a unique random number with the use of a
random sequence generator.
10 We assessed in full text
the first 500 articles according to this random list for
their eligiblity, and extracted relevant data from eligi-
ble trials. Of these, 87 did not meet the eligibility cri-
teria. We used an electronic data extraction form to
capture pivotal information from each trial. We cate-
gorised reported outcomes and individual compo-
nents of any composite outcomes into patient
important outcomes (death, major morbidity, patient
reported outcome) or intermediate outcomes—that is,
those not immediately or directly important to
patients, such as biochemical, physiological, or surro-
gate outcomes. The categorisation of outcome was
based on previously published ranking systems,
1112
with more emphasis on the methods of outcome mea-
surement (see also web extra appendix 2). From the
trials evaluated, we assessed those that were reporting
patient reported outcomes to see whether a previously
validated instrument was used or whether psycho-
metric properties were reported or referenced in the
article.Alldatawereextractedinduplicate.Theresults
and disagreements were discussed untilconsensus was
reached.
Development and validation of a tool for ranking relevance
of patient reported outcomes
Several articles described seven pivotal features of
trials that would need to be considered when making
decisionsabouttheappropriatenessofpatientreported
outcomesinclinicaltrials.
3713-20Weusedtheproposed
framework from these studies to devise a tool that
would allow a systematic and reliable ranking of the
relevance of patient reported outcomes in cardio-
vascular trials into five categories (crucial, important,
potentially relevant, irrelevant, and uncertain) by the
level of importance of patient reported outcomes to
clinical decision making. With the lack of any gold
standards, we sought expert opinion to reach consen-
sus about the validity of the tool. An initial version of
the tool, together with a set of instructions for its use,
was sent to nine experts who were identified on the
basis of previous publications in the area of outcome
measurement and health services research. After
incorporation of the comments received from four
experts, two reviewers (KR and AM) independently
applied the modified and face validated tool to 100
randomly selected articles. The experience gained
from the initial data extraction was used to inform the
final tool (fig 2).
Web extra appendix 2 provides a detailed descrip-
tionofthetool.Briefly,apatientreportedoutcomewas
considered irrelevant in studies that primarily sought
to test a hypothesis useful for understanding the differ-
ences between intervention strategies, without any
claims on changing clinical practice. Studies that
aimed to help make decisions about alternative strate-
gies were categorised as pragmatic trials. If the main
goal of such trials was to improve symptoms, func-
tional status, or quality of life, we considered the
patient reported outcome to be crucial. Otherwise,
ranking of the relevance of patient reported outcomes
depended on several other trial features (see fig 2 and
web extra appendix 2).
Prevalence of patient reported outcomes over time
One study assessed the prevalence of quality of life in
cardiovascular trials and showed that between 1980
and 1997, 2.1% of such trials reported quality of life
and that the rate increased over time (from 0.34% in
1980 to 3.6% in 1997).
6 We replicated and updated
that reported search and extended the timeframe to
2009 to assess the effect of time on reporting of quality
of life in cardiovascular trials.
Reports retrieved (n=2374)
Potentially relevant reports identified (n=998)
Reports randomly selected for full text review (n=500)
Studies excluded because eligibility criteria were not
  met (more than one reason may apply) (n=1376):
    No randomised controlled trial or observational
      analysis of randomised controlled trial (n=906)
    Duplicate reports (n=261)
    No population with cardiovascular disease (CVD) or no
       intervention against CVD (n=226)
     Non-human study (n=1)
Trials included (n=413)
Excluded because eligibility criteria were not met (n=87):
    No randomised controlled trial or observational
      analysis of randomised controlled trial (n=47)
    Duplicate reports (n=30)
    No population with cardiovascular disease (CVD)
       or no intervention against CVD (n=10)
Fig 1 | Search retrieval and study selection process
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We used descriptive statistics to characterise the
included trials. Univariate analyses (χ
2 test, Fisher’s
exact test, and Mantel-Haenszel test for trend)
explored associations of trial characteristics and type
ofoutcome(patientimportant:yesorno)andmeasure-
ment of patient reported outcomes. In the first 50
reviewed trials the prevalence for use of patient
reported outcomes was 14%. We therefore estimated
thatdatafromabout400trialswouldprovidesufficient
information for assessment of associations between
trial features and type of outcomes selected. To allow
forseveralineligibletrialsandduplicatereports,weset
a target of 500 articles to be reviewed in full text.
Excluding the first 100 trials that were evaluated in
the pilot phase for development of the ranking tool,
we used information from the next set of randomly
selected trials, independently extracted by two
reviewers (KR and AM), to estimate the chance cor-
rectedinter-raterreliability.Weweightedtheoutcomes
to account for the closeness of different categories, as
showninthematrix(seewebextraappendix3).Assess-
ment of inter-rater reliability based on the final 330
reports showed a substantial chance corrected inter-
rater agreement between the two investigators:
weighted=0.79; quadratic weighted=0.77.All analyses
were carried out using STATA v 9.1.
RESULTS
Type of reported outcomes
In 93 trials (23%, SE 2%) the primary outcome was
patient important (death, major morbidity, patient
reported outcome), whereas another 92 trials (22%,
SE 2%) combined these with intermediate outcomes
of less or no importance to patients (table 1). In 52 of
these 92 trials (57%) less than half of the events were
attributabletopatientimportantoutcomes—thatis,the
composite outcome was dominated by intermediate
outcomessuchasphysiological,biochemical,orsurro-
gates. All other trials (228 (55%), SE 2%) used inter-
mediate outcomes as their primary outcome. Patient
reportedoutcomeswerereportedin65ofthe413trials
assessed (16%, SE 2%) but were the primary outcome
in only two trials and a coprimary outcome in another
four trials.
Table 1 shows the association between trial charac-
teristics, the type of reported outcomes, and the pre-
sence or absence of patient reported outcomes.
Contrasting the significant association between the
type of primary outcome and several features of the
trials, there was no evidence that the trials reporting
patient reported outcomes were significantly different
from those not reporting patient reported outcomes,
based on the type of primary end point selected, year
of publication, trial design, blinding methods, number
of participants, number of centres, study coordinating
region, or the type of funding. Strong evidence was
foundthatstudiesreportingpatientreportedoutcomes
differed by the condition under investigation and the
typeofintervention.Inparticular,studiesthatincluded
patients with heart failure, arrhythmia (for example,
atrial fibrillation) or “other vascular conditions” (for
example, pulmonary arterial hypertension, peripheral
arterial disease, stroke) were more likely to use patient
Explanatory Pragmatic
Study objective
Superiority Superiority Non-inferiority
Patient important outcome only or composite
outcome with ≥50% patient important outcome
Design Design
Composite outcome with <50%
patient important outcome
Inadequately measured
harm or patients with
chronic symtoms?
Inadequately measured
harm or patients with
chronic symtoms?
Inadequately measured
harm or patients with
chronic symtoms?
Crucial Important
No Yes
Yes No/unsure
No Yes No Yes
Important Potentially
relevant
Crucial
Non-
inferiority
Crucial Important Uncertain
No patient
important
outcome
Crucial
Mainly for symptom relief or functional improvement?
Primary outcomes
Irrelevant
Fig 2 | Flow chart for assessment of relevance of patient reported outcomes in clinical trials. Percentages only apply to trials
that used composite outcomes
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outcomes. Values are numbers (percentages) unless stated otherwise
Feature
All
trials
Primary outcomes dominated
bypatientimportantoutcomes
P
value*
Outcomes included patient
reported outcomes
P
value†
Total 413 133 (32) 65 (16)
Type of primary outcome:
Patient important 93 93 (100)
—
18 (19)
0.39 Biochemical or surrogate 228 0 (0) 36 (16)
Mixed 92 40 (44) 11 (12)
Year of publication:
2005 117 40 (34)
0.7
16 (14)
0.91
2006 102 33 (32) 20 (20)
2007 100 29 (29) 16 (16)
2008 94 31 (33) 13(14)
Trial design:
Parallel 335 116 (35)
0.002
55 (16)
0.83 Crossover 26 1 (4) 3(12)
Other 52 16 (31) 7 (13)
Blinding methods:
Double blind 206 65 (32)
0.92
26 (13)
0.26
Partially blinded 68 22 (32) 11 (16)
Open 132 43 (33) 27 (20)
Unspecified 7 3 (43) 1 (14)
No of participants:
<101 115 4 (3)
<0.001
20 (17)
0.20 101-1000 175 43 (25) 31 (18)
≥1001 123 86 (70) 14 (11)
Study coordinating region:
North America 170 31 (18)
0.02
31 (18)
0.49 Europe 206 30 (15) 30 (15)
Rest of world 37 4 (11) 4 (11)
No of centres:
1 145 15 (10)
<0.001
20 (14)
0.45 2-10 66 16 (24) 11 (17)
>11 202 102 (51) 34 (17)
Funding:
For profit 185 64 (35)
0.001
27 (15)
0.61
Not for profit 121 41 (34) 22 (18)
Mixed 54 23 (43) 10 (19)
Not reported 53 5 (9) 6 (11)
Disease or condition under investigation:
Acute coronary syndromes 53 23 (43)
0.005
4( 8 )
<0.001
Other coronary artery disease 110 20 (18) 7 (6)
Heart failure 55 14 (25) 28 (51)
Arrhythmia 15 5 (33) 3 (20)
Other cardiac disease 20 8 (40) 0 (0)
Other vascular conditions 75 31 (41) 16 (21)
Healthyoratriskofcardiovasculardisease 85 32 (38) 7 (8)
Type of intervention:
Drug 250 86 (34)
0.06
34 (14)
<0.001
Drug v placebo 141 45 (32) 22 (16)
Drug v active drug 81 33 (41) 4 (5)
Drug v other 28 8 (29) 8 (29)
Coronary intervention or devices 62 14 (23) 4 (6)
Non-coronary intervention 34 12 (35) 6 (18)
Lifestyle or nutrition 31 5 (16) 10 (32)
Other interventions 36 16 (44) 11 (31)
*For comparison against trials where primary outcomes were not dominated by patient important outcomes.
†For comparison against studies that had not included patient reported outcomes in their report.
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people with coronary artery disease or when inter-
ventions were aimed at primary prevention of cardio-
vascular conditions. Studies that assessed the effect of
lifestyle interventions, nutrition, and those with “other
interventions,” such as reminder systems or screening
tests,were also morelikely to use patientreportedout-
comes, whereas studies of coronary intervention or
other procedures were less likely to do so.
Quality and types of reported instruments for measuring
patient reported outcomes
Of the 65 trials reporting patient reported outcomes,
onlyseven(11%)usedadhocmeasures(thatis,nopre-
viously validated instrument used or psychometric
properties reported or referenced) or proxies for
assessment of patients’ health status, and in another
three (5%) published information was insufficient to
ascertain the properties of the instruments used. The
other 55 trials (85%) used at least one validated instru-
ment (seven trials reported three different instruments
and 16 reported two instruments). The most com-
monly useddisease specificinstrumentswere the Min-
nesota living with heart failure questionnaire and the
Seattle angina questionnaire, which were used in 18
and five different studies, respectively. The most com-
monly used generic instruments were the short-form
36 health survey and the EuroQol 5-D, which were
used in nine and five studies, respectively.
Prevalence of reporting on patient reported outcomes over
time
The replicated and updated search from a previous
study showed that the proportion of cardiovascular
trials that also mentioned quality of life has increased
more than threefold since 1997 (fig 3). By 2009, about
14% of trials mentioned quality of life. However, these
crude figures should be interpreted with caution as
theywereonlybasedonasimplebibliographicsearch,
which may not reflect actual use of patient reported
outcomes.
Relevance of reporting on patient reported outcomes
Table 2showstheassessedlevelofrelevanceofpatient
reported outcomes overall and by the status of
reporting of such outcomes to individual trials. Patient
reported outcomes were found to be crucial for
informed clinical decision making in 93 trials (23%).
Thesewere mostly (n=57) trialsthathad set out chiefly
to improve patients’ wellbeing or quality of life. For
example, the Canadian Cardiac Randomized Evalua-
tion of Antidepressant and Psychotherapy Efficacy
(CREATE) trial investigated the effect of citalopram
and interpersonal psychotherapy on depression in
people with coronary artery disease (and had used
two validated scoring tools for the assessment of
depression).
21 A few other studies in the category of
“patient reported outcome crucial” were trials that
aimed to change clinical practice, but their outcomes
weredominatedbyonesofquestionableimportanceto
thepatients.Atthesametimethesetrialsfailedtomea-
sure adequately the effect of harms or had included
patients who had chronic symptoms for whom
improvementinqualityoflifewould havebeenhighly
desirable. For example, the Plasma Brain natriuretic
Peptide-Guided Therapy to Improve Outcome in
Heart Failure: The STARS-BNP Multicenter Study
trialassessedtheeffectofplasmabrainnatriureticpep-
tideguidedtherapyondeathandadmissiontohospital
in patients with chronic heart failure.
22 However,
deaths due to heart failure accounted for only about
15% of the composite outcome, with the remainder
beingadmissionstohospital.Overall,37ofthe93trials
in which patient reported outcomes would have been
crucial reported such outcomes.
Patientreportedoutcomeswerejudgedtobeimpor-
tant in 81 ofthe trials(20%),of which 15 reportedsuch
outcomes.Themajorityoftheseweresuperioritytrials
that had used mostly patient important outcomes but
had not adequately measuredharms or had included a
patient population with chronic symptoms. Studies
that did not measure harm adequately were mostly
trials of interventions known to be associated with a
substantial bleeding risk. For example, the value of a
decreaseinbloodhaemoglobinlevels,whichwascom-
monly used as a criterion for major bleeding, is not
obvious from the patient’s perspective. The combina-
tion of such harms with potential benefits of the inter-
ventionhasbeenusedinanattempttoestimatethenet
clinical benefit.
23 However, such combined effects
without any valuation by the patients have made the
interpretation of the results even more challenging.
24
Inanother59trials(14%)patientreportedoutcomes
were judged to be potentially relevant. These were
trials that aimed to inform clinical decision making
beyond the relief of symptoms or improvements in
quality of life, had mainly used patient important out-
comes as the primary end point, and had measured
harm adequately (if expected or possible). In this set-
ting, patient reported outcomes were thought to be
only potentially relevant, mainly for estimation of the
preferencebasedoutcomesofthe intervention andthe
calculation of quality adjusted life years as part of eco-
nomic evaluation.
Patient reported outcomes were judged to be irrele-
vant in 93 trials (23%). These were explanatory trials
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Fig 3 | Prevalence of cardiovascular trials that also mentioned
“quality of life”
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directly. For example, one trial investigated the effect
of angiotensin receptor blockers on blood kinin levels
toexplorepossiblemechanismsofactionofthistypeof
drugs.
25 Only two trials in this category used patient
reportedoutcomes, giving little evidence for the possi-
bility of misuse of patient reported outcomes in cir-
cumstances where such information would be of
limited value.
The relevance of patient reported outcomes was
ranked as uncertain in 87 trials (21%). These trials
wereprimarilylimitedbythelackofpatientimportant
outcomes to address a clinically relevant question. In
such trials, judgment on the incremental value of
patient reported outcomes would have been highly
hypothetical. For example, in a trial that aimed to
assess the efficacy of reperfusion therapy 12 hours
aftertheonsetofsymptomsinpatientswithacutemyo-
cardial infarction but used infarct size as its primary
end point,
26 assessment of the level of relevance of
patientreportedoutcomeswouldhavebeensecondary
because to make an informed decision on patient care
such a trial would in the first instance be expected to
usepatientimportantoutcomesbeforetheincremental
valueofpatientreportedoutcomescouldbeevaluated.
DISCUSSION
Patient reported outcomes were reported in 16% of
contemporary cardiovascular trials published in
major cardiology and general medical journals during
2005-8. Reported patient reported outcomes were
mostly validated instruments and mostly used in set-
tings where such information would have been highly
relevant to clinical decision making. Although patient
reportedoutcomeswerejudgedtobeoflittlevaluetoa
large proportion of, mostly explanatory, cardio-
vascular trials, still more than two thirds of trials in
which patient reported outcomes were judged to be
important or crucial for clinical decisionmaking failed
to report such outcomes. In addition, composite out-
comes in many trials were often dominated by out-
comes that were not immediately important to
patients.
Threemajorareaswereidentifiedinthisstudywhere
the measurement of patient reported outcomes was
underused but could have made a valuable contribu-
tion to interpretation of the study findings. Firstly,
many trials that were primarily concerned with relief
of symptoms and improvement in quality of life failed
to use patient reported outcomes, and even when they
did these were rarely the primary outcome (contribut-
ing to the lack of impact of such findings on informing
clinical practice
27).
Secondly, shortcomings in reporting of patient
reported outcomes were also observed in trials that
assessedbenefitsofaninterventioninlightofconsider-
able harms caused by the same intervention. While it
could be argued that most interventions are likely to
have multiple effects, desired and undesired, expected
and unexpected, it would be inappropriate to demand
measurementofpatientreportedoutcomesinalltrials.
Standard safety monitoring of trials (despite all its lim-
itations) and crude reporting of events might be suffi-
cient for clinical decision making in circumstances
where the spectrum of harms is reasonably well
known and clinically measurable.
28 However, issues
arise when potential harms are substantial and their
objectiveevaluationisnotdirectlyrelevanttopatients.
One common area identified in this study was the
assessment of the risk of bleeding in trials aiming to
reducetheriskofcardiovascularevents.Theinvestiga-
tors used a diversity of methods for measurement and
classification of bleeding, with some of these being
purely based on objective laboratory measures with
little relevance to patients. This bears the risk of inva-
lidating comparisons between the different outcome
components within the same study, as well as between
studies reporting similar outcomes.
29 A few investiga-
torshaveattemptedtoestimatethenetclinicaleffectby
combining harms and benefits into a single composite
outcome. However, such an approach would assume
that detection methods for different types of outcomes
are equally sensitive and that different types of events
have a similar clinical weight. Since such conditions
cannot easily be met in practice,
30 and in the absence
of valid and meaningful scoring systems for measure-
ment of such harms, patient reported outcomes could
offer an alternative method for assessment of the
impact of such effects on patients. Preference based
instruments for patient reported outcomes (that is,
instruments that provide relative values for different
health states
23), would allow an estimate of the
weighted average of benefits and harms from the
patient’s perspective and could provide a common
denominator for different types of outcomes.
Thirdly, the use of patient reported outcomes could
beimprovedinthegroupoftrialsusingcompositeend
points that incorporate outcomes of different impor-
tance to the patients. This can be particularly proble-
matic when outcomes that are less important to the
patientsdominatetheresultsorwhentreatmenteffects
are discordant and qualitatively different across the
individual components. The current study shows that
in over half of the studies with mixed primary out-
comes, the findings were dominated by the inter-
mediate outcomes of questionable relevance to
patients. A generic preference based instrument for
patient reported outcomes would have the ability to
evaluate the overall effect of such outcomes from the
patient’s perspective.
31 Serial measurements would
Table 2 |Comparison of reporting and relevance of patient reported outcomes (PROs) to
clinical decision making. Values are numbers (percentages) unless stated otherwise
Level of relevance to clinical
decision making All trials
Trialsnotreporting
PROs
Trials reporting
PROs
P value
for trend*
Crucial 93 (23) 56 (60) 37 (40)
<0.001
Important 81 (20) 66 (81) 15(19)
Potentially relevant 59 (14) 56 (95) 3 (5)
Irrelevant 93 (23) 91 (98) 2 (2)
Uncertain 87 (21) 79 (91) 8 (9)
*Trend test excludes trials with uncertain level of relevance.
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that commonly count the first occurrence of events
onlyandignorerecurrences,eveniftheseareofgreater
importance to patients.
Concerns have been raised that widespread recom-
mendations from funding agencies and regulatory
bodiesforthe useofpatientreportedoutcomesinclin-
ical trials may lead to inappropriate use of such out-
comes. In this study only 5% of trials in which patient
reported outcomes were ranked as irrelevant reported
such outcomes, therefore dismissing any concerns for
substantial misuse. However, this may be an underes-
timate because our protocol included high quality
medical journals only and the trials may not be repre-
sentative of all cardiovascular trials. In addition, the
prevalence of reporting patient reported outcomes
was based on the published information. Some inves-
tigators may have measured but not reported such
outcomes.
27
Strengths and limitations of the review
To the best ofour knowledge,thisis the firststudy that
has devised a tool for the reliable and transparent
assessment of the relevance of patient reported out-
comes to cardiovascular trials. The tool was validated
byexperts,appliedtoalargesetofcardiovasculartrials
with a high inter-rater reliability, and may guide
researchers in the future at the design stage of trials.
Although a certain degree of judgment was inevitable
in categorising trials, discrepancies between indepen-
dent assessors were small and easily resolved through
discussion, with no material effect on the overall find-
ings.Thefocusofthecurrentstudywastheassessment
of patient reported outcomes as study outcome mea-
sures.Weacknowledgethatpatientreportedoutcomes
can play an important part at other stages of clinical
trials,suchasduringrecruitmenttoidentifypotentially
eligible participants or at baseline for categorisation of
participants into different risk groups.
32 We also
acknowledge that patient reported outcomes will not
be the panacea for all existing challenges of outcome
selection in clinical trials. Lack of suitable instruments
and the somewhat sophisticated requirements for ana-
lysis and interpretation of results
33 may have contribu-
ted to their underuse. Inadequate blinding of study
participants may also prevent investigators from
using patient reported outcomes, as such outcomes
are more prone to bias than more objective outcomes.
However,wefoundnoevidencethatthetypeofblind-
ing correlated with use of patient reported outcomes.
Conduct of trials is time consuming and many of the
assessed trials may have been initiated a few years
before publication, when guidelines on use of patient
reported outcomes in trials were unavailable. Other
feasibility issues such as the need for larger sample
sizes and longer duration of follow-up may also be dif-
ficulttoovercome.However,thestudysizeornumber
of participants was not associated with the use of
patient reported outcomes in the current study. This
study was not designed to investigate the underlying
causesofunderuseofpatientreportedoutcomes.Qua-
litative studies may be useful to help understand the
investigators’ approach towards outcome selection
and to explain why selected outcomes are often inade-
quate.
Conclusions and policy implications
Despite the continued rise in reporting of patient
reported outcomes in cardiovascular trials, such out-
comes were still underused in many trials, even after
taking account of their relevance to individual trials.
The present study reiterates the need for selection of
morepatientfocusedoutcomesandhighlightssomeof
theproblemsassociatedwithcompositeoutcomesand
assessment of harms in cardiovascular trials. In such
areas, more widespread use of patient reported out-
comes may be a valuable complement to the tradi-
tional clinical outcomes. Involvement of patients and
expertsinoutcomesat thedesignstageofclinicaltrials
may help in the process of selection of outcomes that
are relevant and meaningful to those who potentially
will be affected by them.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Patient reported outcomes assess the effect of trial interventions from patients’ perspectives
and are particularly useful when interventions aim to improve symptoms or functional status
Studies report a low prevalence of patient reported outcomes particularly in cardiovascular
trials, perhaps because many cardiovascular interventions aim to affect mortality and major
morbidity
Littleinformationisavailableontheappropriatenessoftheuseofpatientreportedoutcomes
in contemporary cardiovascular trials
WHAT THIS STUDY ADDS
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